Tirzepatide was associated with significant reductions in weight primarily due to fat mass loss while preserving lean mass in obesity.

The Food and Drug Administration said Thursday it’s standing by its earlier decision that the shortage of tirzepatide — the active ingredient in Eli Lilly’s diabetes and weight loss drugs Mo ...

In the final weeks of his administration, President Biden’s Food and Drug Administration quietly ended the “shortage” of tirzepatide, a popular GLP-1 medication. That means on March 19 ...

Doses of 5 milligrams (mg) to 15mg of tirzepatide can help those with type 2 diabetes lose up to 15 percent of their body weight, and those without type 2 diabetes lose up to 21 percent of their ...

In the 731-patient SUMMIT study, participants were randomly assigned to either tirzepatide at a dose of between 2.5mg and 15mg per week or placebo, on top of their current heart failure treatment.

Hollie Adams/Reuters In October, a compounding industry group, the Outsourcing Facility Association, filed a lawsuit against the FDA's decision that there was no longer a shortage of tirzepatide ...

The dosage range of tirzepatide is 2.5mg to 15mg, taken once weekly as a subcutaneous injection. Tirzepatide has the highest ...

Larger outsourcing facilities, which are FDA-regulated and can create prescription-specific compounded drugs as well as bulk orders, must cease compounding, distributing or dispensing tirzepatide ...

Tirzepatide was previously shown to provide sustained weight reductions in adults with obesity. New longer-term findings in adults with both obesity and prediabetes are summarized in a short video.

Eli Lilly's latest clinical readout for dual GIP/GLP-1 agonist tirzepatide is a big one, with data suggesting the drug can reduce the risk of developing type 2 diabetes in overweight and obese ...

Get Instant Summarized Text (Gist) Tirzepatide, a dual-incretin, was evaluated for its effects on cardiovascular and kidney biomarkers in overweight and obese adults with type 1 diabetes. Over 21 ...